These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32835900)

  • 1. Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.
    Mantero V; Abate L; Balgera R; Basilico P; Salmaggi A; Cordano C
    Mult Scler Relat Disord; 2020 Nov; 46():102453. PubMed ID: 32835900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis.
    Landi D; Ponzano M; Nicoletti CG; Cecchi G; Cola G; Mataluni G; Mercuri NB; Sormani MP; Marfia GA
    Mult Scler Relat Disord; 2020 Oct; 45():102359. PubMed ID: 32663793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
    Zabalza A; Cárdenas-Robledo S; Tagliani P; Arrambide G; Otero-Romero S; Carbonell-Mirabent P; Rodriguez-Barranco M; Rodríguez-Acevedo B; Restrepo Vera JL; Resina-Salles M; Midaglia L; Vidal-Jordana A; Río J; Galan I; Castillo J; Cobo-Calvo Á; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Eur J Neurol; 2021 Oct; 28(10):3384-3395. PubMed ID: 33340215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients.
    Oncel I; Alici N; Solmaz I; Oge DD; Ozsurekci Y; Anlar B
    Pediatr Neurol; 2022 Sep; 134():7-10. PubMed ID: 35772229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit.
    Sepúlveda M; Llufriu S; Martínez-Hernández E; Català M; Artola M; Hernando A; Montejo C; Pulido-Valdeolivas I; Martínez-Heras E; Guasp M; Solana E; Llansó L; Escudero D; Aldea M; Prats C; Graus F; Blanco Y; Saiz A
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33504634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.
    Piñar Morales R; Ramírez Rivas MA; Barrero Hernández FJ
    Neurologia (Engl Ed); 2021; 36(9):698-703. PubMed ID: 34103271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021.
    Naghavi S; Kavosh A; Adibi I; Shaygannejad V; Arabi S; Rahimi M; Mazaheri S; Ashtari F
    Mult Scler Relat Disord; 2022 Jan; 57():103335. PubMed ID: 35158427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 in multiple sclerosis patients and risk factors for severe infection.
    Chaudhry F; Bulka H; Rathnam AS; Said OM; Lin J; Lorigan H; Bernitsas E; Rube J; Korzeniewski SJ; Memon AB; Levy PD; Schultz L; Javed A; Lisak R; Cerghet M
    J Neurol Sci; 2020 Nov; 418():117147. PubMed ID: 32980780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo.
    Komoni E; Jashari F; Boshnjaku D; Myftiu B; Pushka M; Blyta A; Nallbani-Komoni R
    Med Sci Monit; 2024 Jan; 30():e942992. PubMed ID: 38287659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
    Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
    Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
    Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
    Front Immunol; 2020; 11():1059. PubMed ID: 32477373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada.
    Solomon JM; Jones A; Hohol M; Krysko KM; Muccilli A; Roll A; Rotstein D; Schneider R; Selchen D; Vosoughi R; Baral SD; Oh J
    Mult Scler Relat Disord; 2022 Feb; 58():103509. PubMed ID: 35030366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy.
    Crescenzo F; Marastoni D; Bovo C; Calabrese M
    Mult Scler Relat Disord; 2020 Sep; 44():102372. PubMed ID: 32650121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The course of COVID-19 infection in patients with multiple sclerosis-The experience of one center based on the population of Upper Silesia.
    Nowak-Kiczmer M; Kubicka-Bączyk K; Niedziela N; Adamczyk B; Wierzbicki K; Bartman W; Adamczyk-Sowa M
    Mult Scler Relat Disord; 2021 Jul; 52():102984. PubMed ID: 34000683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis.
    Sahraian MA; Azimi A; Navardi S; Ala S; Naser Moghadasi A
    Mult Scler Relat Disord; 2020 Nov; 46():102472. PubMed ID: 32890817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
    Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland.
    Czarnowska A; Kapica-Topczewska K; Zajkowska O; Adamczyk-Sowa M; Kubicka-Bączyk K; Niedziela N; Warmus P; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Nowak K; Bartosik-Psujek H; Lech B; Perenc A; Popiel M; Kucharska-Lipowska M; Chorąży M; Tarasiuk J; Mirończuk A; Kochanowicz J; Lasek-Bal A; Puz P; Maciejowska K; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Zwiernik J; Michałowska A; Nosek K; Zwiernik B; Lewańczyk B; Brola W; Kułakowska A
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a MERS-CoV Endemic Area.
    Barry M; AlMohaya A; AlHijji A; Akkielah L; AlRajhi A; Almajid F; Alsharidi A; Al-Shahrani FS; Alotaibi NH; Alanazi A; Ghonem L; Alhetheel A; Alsubaie S; Memish ZA
    J Epidemiol Glob Health; 2020 Sep; 10(3):214-221. PubMed ID: 32954712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.